insurance doesn't cover glp 1 Millions could benefit from GLP-1 medications. So why can't they get them? Experts at #MIGlobal2026 point to three major barriers: • High costs • coverage gaps • Care models that don't Could your insurance carrier drop

Vaginal Estradiol: A Necessary Distinction Systemic estradiol can influence metabolic regulation, while vaginal estradiol primarily treats local symptoms

For the first time in the history of obesity medications we see weight loss efficacy of a magnitude that might raise concern about excessive loss of lean body tissue due to the initial pronounced reduction in energy intake and subsequent risk of protein deficiency

These conditions often coexist with obesity and may influence your eligibility for treatment with Semaglutide GLP-1

A.CaccioppoliC.Andrulli BuccheriV.CignarelliA.et al (2017)

Everything comes with risks

IQVIA prescription data put ongoing users at approximately 1.5 million in March 2025 alone, rising to over 2 million paying privately by July 2025